Hepsera Selected as U.S. Trade Name for Adefovir Dipivoxil

FOSTER CITY, Calif., Aug 28, 2002 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) announced that it has selected Hepsera(TM) as the U.S. trade name for adefovir dipivoxil, the company's investigational treatment for patients with chronic hepatitis B. Gilead's application to market Hepsera is currently under review by the U.S. Food and Drug Administration (FDA). On August 6, the FDA's Antiviral Drugs Advisory Committee voted unanimously in support of approval of the drug. The FDA will consider the Committee's recommendations as it completes its priority review of Hepsera, with an action date of September 21.

    About Hepsera
Hepsera, a nucleotide analogue for the potential treatment of chronic hepatitis B, works by blocking HBV DNA polymerase, an enzyme involved in the replication of HBV in the body. The drug has been studied in treatment-naive patients with compensated liver disease, including both HBeAG positive and HBeAG negative (presumed precore mutant) hepatitis B. The drug also has been studied in patients who were treated with and developed resistance to lamivudine, including patients wait-listed for or who had received a liver transplant. As an investigational compound, Hepsera has not yet been determined safe or efficacious in humans for its ultimate intended use.

    About Hepatitis B
Worldwide, there are approximately 350 million chronic carriers of hepatitis B, of which approximately one million die each year from complications of the disease, making chronic hepatitis B one of the 10 leading causes of death. Complications of chronic hepatitis B include cirrhosis (scarring of the liver), liver failure and primary liver cancer (hepatocellular carcinoma). Between one-quarter and one-third of people with chronic hepatitis B are expected to develop progressive liver disease. Patients infected with the precore mutant strain of hepatitis B may be predisposed to more severe and progressive liver injury. Precore mutant hepatitis B infects up to approximately 50 percent of the 350 million chronic hepatitis B carriers worldwide and is most prevalent in countries of the Mediterranean and Southeast Asia, where between 30-80 percent of chronic hepatitis B patients are estimated to be infected with this strain.

    Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. Such risks and uncertainties include the risk that the FDA may not follow the advice of the advisory committee and may refuse to grant regulatory approval for Hepsera. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in the Gilead Annual Report on Form 10-K for the year ended December 31, 2001 and in Gilead's Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's Web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT:          Gilead Sciences
                  Susan Hubbard, 650/522-5715 (Investors)
                  Amy Flood, 650/522-5643 (Media)

URL:              http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.